

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar International Holdings Company Limited

巨星國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

PROPOSED CHANGE OF COMPANY NAME

The Board of the Company proposes to change the English name of the Company from “Yestar International Holdings Company Limited” to “Yestar Healthcare Holdings Company Limited” and to change the dual foreign name in Chinese of the Company from “巨星國際控股有限公司” to “巨星醫療控股有限公司”.

The Proposed Change of Company Name is subject to the fulfilment of the conditions set out in the section headed “Conditions for the Proposed Change of Company Name” in this announcement.

A circular containing, amongst other things, (i) details of the Proposed Change of Company Name; and (ii) a notice convening the EGM and related proxy form will be despatched to the Shareholders on or before 14 December 2016.

The Company will make further announcement as and when appropriate on the effective date of the Proposed Change of Company Name and the new English and Chinese stock short names of the Company upon the Proposed Change of Company Name becoming effective.

PROPOSED CHANGE OF COMPANY NAME

The board (the “Board”) of directors (the “Directors”) of Yestar International Holdings Company Limited (“the Company”, together with its subsidiaries, the “Group”) proposes to change the English name of the Company from “Yestar International Holdings Company Limited” to “Yestar Healthcare Holdings Company Limited” and to change the dual foreign name in Chinese of the Company from “巨星國際控股有限公司” to “巨星醫療控股有限公司” (the “Proposed Change of Company Name”).

REASON FOR THE PROPOSED CHANGE OF COMPANY NAME

It is the Group’s strategy to develop its medical consumable business through the acquisition of medical consumable companies. Since 2014, the Group has transformed itself from a leading provider of colour photographic paper and imaging products in the PRC into a high margin medical consumables manufacturer and distributor in the PRC. In 2016, the Group has

further acquired 70% equity interests in each of 3 medical consumable companies in the PRC. In view of the above, the medical consumable business shall be the key performance driver for the Group.

The Board considers that the Proposed Change of Company Name will provide the Company with a more appropriate identification of its principal business and the new corporate identity and image of the Company will benefit the Company and its shareholders (the “Shareholders”) as a whole.

CONDITIONS FOR THE PROPOSED CHANGE OF COMPANY NAME

The Proposed Change of Company Name is subject to the following conditions:

- (i) the passing of a special resolution by the Shareholders at an extraordinary general meeting (“EGM”) of the Company approving the Proposed Change of Company Name; and
- (ii) the Registrar of Companies in the Cayman Islands granting approval for the use by the Company of the proposed English name of “Yestar Healthcare Holdings Company Limited” and the proposed Chinese name of “巨星醫療控股有限公司” as the dual foreign name of the Company and the entering of the proposed new English name and the proposed new dual foreign name in Chinese of the Company into the register of companies by the Registrar of Companies in the Cayman Islands.

Subject to the satisfaction of the conditions set out above, the Proposed Change of Company Name will take effect from the date of the certificate of incorporation on change of name issued by the Registrar of Companies in the Cayman Islands. The Company will then carry out all necessary filing procedures with the Companies Registry in Hong Kong.

EFFECTS OF THE PROPOSED CHANGE OF COMPANY NAME

The Proposed Change of Company Name will not affect any of the rights of the Shareholders. Other than the change to the English stock short name and the Chinese stock short name to be announced by the Company following the Proposed Change of Company Name becoming effective, the trading arrangements for the shares of the Company on The Stock Exchange of Hong Kong Limited will not be affected. All existing share certificates of the Company in issue bearing the existing English and Chinese names of the Company will, after the Proposed Change of Company Name becomes effective, remain to be evidence of title to shares of the Company and will continue to be valid for trading, settlement and registration purposes. Accordingly, there will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates bearing the new English and Chinese names of the Company. Under the Cayman Islands Companies Law, the register of members of the Company is by statute regarded as prima facie evidence of title to the shares issued by the Company.

Share certificates of the Company that are issued on or after the Proposed Change of Company Name becoming unconditional will be issued under the new English and Chinese names of the Company. The English and Chinese stock short names of the Company will also be changed.

GENERAL

A circular containing, amongst other things, (i) details of the Proposed Change of Company Name; and (ii) a notice convening the EGM and related proxy form will be despatched to the Shareholders on or before 14 December 2016.

The Company will make further announcement as and when appropriate on the effective date of the Proposed Change of Company Name and the new English and Chinese stock short names of the Company upon the Proposed Change of Company Name becoming effective.

By Order of the Board
Yestar International Holdings Company Limited
巨星國際控股有限公司
Hartono James
Chairman, CEO and Executive Director

Hong Kong, 9 December 2016

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong, Mr. Chan Chung Man; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Karsono Tirtamarta (Kwee Yoe Chiang) and Mr. Sutikno Liky.